Femtech World is excited to reveal the shortlist for this year’s Menopause Innovation award.
The award is one of 11 to be celebrated at Femtech World’s second annual awards event.
The Menopause Innovation award celebrates a pioneering advancement that has significantly improved the experience and care for those going through menopause.
This award will highlight innovations that have provided new solutions for managing menopausal symptoms, improving quality of life and empowering individuals with knowledge and support.
The award is sponsored by venture capital firm, Cross-Border Impact Ventures.
The firm targets both financial returns in line with venture returns and positive impact on the health of women, children and adolescents inclusively and globally for each investment it makes.
A winner from the shortlist will be chosen by the sponsor and announced at a virtual ceremony on May 28.
Congratulations to the shortlisted organisations and thank you to everyone who entered.
Menopause Innovation Shortlist
Eli Health’s Hormometer revolutionises care with real-time, at-home saliva testing, offering instant, affordable insights into hormonal fluctuations.
Launching progesterone testing in Q1 2025, with estradiol testing in development, Eli is building a comprehensive hormone monitoring solution.
Unlike lab tests, our AI-powered, needle-free technology provides continuous tracking for around $8 per test.
By putting personalised hormone insights directly into women’s hands, Eli Health is redefining menopause care—making it data-driven, accessible, and empowering
Mira’s Menopause Transitions Kit goes beyond merely treating symptoms, empowering women to proactively understand and navigate their entire menopause transition.
Traditional tests offer only snapshots of fluctuating hormones like FSH, making it difficult to pinpoint perimenopause or menopause onset.
Mira’s AI-powered kit, however, provides continuous hormone tracking, giving women meaningful data about their reproductive health from the comfort of home.
This is invaluable for those looking to conceive or avoid pregnancy as they gain clarity on their fertility status, as well as for those experiencing new symptoms who want to take control of their health.
Osteoboost is redefining how women protect their bone health during and after menopause, a time when estrogen decline accelerates bone loss and increases the risk of life-altering fractures.
This new breakthrough wearable device is the first and only FDA-cleared, non-drug treatment specifically designed to treat low bone density in postmenopausal women.
Bone loss occurs rapidly during menopause, leaving women more vulnerable to osteoporosis. Osteoboost delivers precision vibration to the lumbar spine and hips–areas most at risk for fractures–using NASA-inspired vibration technology.
With a commitment to empowering women’s health through early intervention, Osteoboost slows age-related bone loss, helping women maintain their independence and mobility well beyond menopause and offering hope for strong, confident, and active golden years.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.
